Walleye Capital LLC Arcellx, Inc. Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$49.74 - $66.98 $2.64 Million - $3.55 Million	-53,064 Reduced 56.33%	41,144 $2.27 Million
Q1 2024 May 15, 2024	SELL	$51.85 - $73.49 $1.25 Million - $1.77 Million	-24,127 Reduced 20.39%	94,208 $6.55 Million
Q4 2023 Feb 14, 2024	SELL	$31.75 - $57.99 $3.11 Million - $5.68 Million	-97,935 Reduced 45.28%	118,335 $6.57 Million
Q3 2023 Nov 21, 2023	SELL	$31.51 - $37.4 $125,598 - $149,076	-3,986 Reduced 1.81%	216,270 $7.76 Million
Q3 2023 Nov 14, 2023	BUY	$31.51 - $37.4 $82,619 - $98,062	2,622 Added 1.2%	220,256 $7.9 Million
Q2 2023 Aug 14, 2023	BUY	$27.49 - $46.9 $1.57 Million - $2.68 Million	57,191 Added 35.65%	217,634 $6.88 Million
Q1 2023 May 15, 2023	BUY	$26.92 - $33.94 $3.88 Million - $4.89 Million	144,173 Added 886.13%	160,443 $4.94 Million
Q4 2022 Feb 14, 2023	SELL	$17.18 - $33.0 $974,672 - $1.87 Million	-56,733 Reduced 77.71%	16,270 $504,000
Q3 2022 Nov 14, 2022	BUY	$16.67 - $22.04 $791,908 - $1.05 Million	47,505 Added 186.31%	73,003 $1.37 Million
Q2 2022 Aug 08, 2022	SELL	$7.21 - $24.43 $414,337 - $1.4 Million	-57,467 Reduced 69.27%	25,498 $461,000
Q1 2022 May 16, 2022	BUY	$12.97 - $19.14 $1.08 Million - $1.59 Million	82,965 New	82,965 $1.16 Million

204

44.2M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.47B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.